DaTscan (Ioflupane I 123 Injection)-a radiopharmaceutical indicated for striatal dopamine transporter visualization using single-photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult patients with suspected parkinsonian syndromes.
DaTscan may be used to help differentiate essential tremor from tremor due to Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy.
The effectiveness as a screening or confirmatory test and for monitoring disease progression or response to therapy has not been established.
Contraindicated in patients with known hypersensitivity to the active substance, any of the excipients, or iodine.
Hypersensitivity reactions, generally consisting of skin erythema and pruritus, have been reported.
The DaTscan injection may contain up to 6% of free iodide (iodine 123).
To decrease thyroid accumulation of I-123, block the thyroid gland at least one hour before administration of DaTscan; failure to do so may increase the long-term risk for thyroid neoplasia.
Headache, nausea, vertigo, dry mouth, or dizziness of mild to moderate severity were reported.
Drugs that bind to the dopamine transporter with high affinity may interfere with the image.
It is unknown whether it can cause fetal harm or increase the risk of pregnancy loss in pregnant women.
Like all radiopharmaceuticals, it may cause fetal harm, depending on the stage of fetal development and the magnitude of the radionuclide dose.
Radioactive iodine products cross the placenta and can permanently impair fetal thyroid function.
It is not known whether it is excreted into human milk; however, I-123 is excreted into human milk. infant.
Its safety and efficacy have not been established in pediatric patients.
It is excreted by the kidney; patients with severe renal impairment may have increased radiation exposure and altered images.
It emits radiation and must be handled with safety measures to minimize radiation exposure to clinical personnel and patients.